Background-Stearoyl-CoA desaturase 1 (SCD1) is a critical regulator of energy metabolism and inflammation. We have previously reported that inhibition of SCD1 in hyperlipidemic mice fed a saturated fatty acid (SFA)-enriched diet prevented development of the metabolic syndrome, yet surprisingly promoted severe atherosclerosis. In this study we tested whether dietary fish oil supplementation could prevent the accelerated atherosclerosis caused by SCD1 inhibition. Methods and Results-LDLr Ϫ/Ϫ , ApoB 100/100 mice were fed diets enriched in saturated fat or fish oil in conjunction with antisense oligonucleotide (ASO) treatment to inhibit SCD1. As previously reported, in SFA-fed mice, SCD1 inhibition dramatically protected against development of the metabolic syndrome, yet promoted atherosclerosis. In contrast, in mice fed fish oil, SCD1 inhibition did not result in augmented macrophage inflammatory response or severe atherosclerosis. In fact, the combined therapy of dietary fish oil and SCD1 ASO treatment effectively prevented both the metabolic syndrome and atherosclerosis. Conclusions-SCD1 ASO treatment in conjunction with dietary fish oil supplementation is an effective combination therapy to comprehensively combat the metabolic syndrome and atherosclerosis in mice. (Arterioscler Thromb Vasc Biol. 2010;30:24-30.)
I t has been estimated that nearly a quarter of American adults have the metabolic syndrome. [1] [2] [3] Inhibition of stearoyl-CoA desaturase 1 (SCD1) has been proposed as an attractive strategy for preventing most aspects of the metabolic syndrome including obesity, 4 -9 insulin resistance, 4, 6, 10, 11 hypertriglyceridemia, 6, [12] [13] [14] and hepatic steatosis. 8, 9, 12, 15, 16 However, several unwanted side effects are associated with SCD1 inhibition or deletion, including alopecia [17] [18] [19] [20] and accelerated atherosclerosis. 21, 22 We have previously shown that the accelerated atherosclerosis seen with SCD1 ASOmediated inhibition is associated with saturated fatty acid (SFA) enrichment of macrophage membranes, and enhanced proinflammatory signaling through toll-like receptor 4 (TLR4). 21 Likely through a similar mechanism, mice lacking SCD1 have enhanced dextran sulfate sodium (DSS)-and bacterial-induced inflammatory gene expression and exaggerated colitis. 23 These recent studies [21] [22] [23] suggest that SCD1 may serve a protective function against proinflammatory signaling.
It is reasonable to assume that many of the inflammationlinked side effects seen with SCD1 inhibition stem from the abnormal accumulation of SCD1 substrates, saturated fatty acids, in multiple tissues. Indeed, there is a large body of evidence that SFAs are potent proinflammatory molecules, linking these SCD1 substrates to a number of inflammatory diseases. 24 -34 In fact, recent evidence suggests that SFAs can activate multiple toll-like receptors (TLRs), which play a key role in innate immunity. 24, 28, 29, [31] [32] [33] [34] Furthermore, TLR4 is necessary for SFAs to induce obesity, insulin resistance, and vascular inflammation in rodents. 24 -27 Therefore, one of the key roles of SCD1 may be to suppress inflammation by preventing excessive accumulation of SFA-derived TLR4 ligands. Interestingly, long chain -3 polyunsaturated fatty acids (-3 PUFA) have been shown to counteract SFAinduced TLR4 activation in cultured macrophage and dendritic cell systems. 28,30 -33 In parallel, there is strong evidence that dietary -3 PUFA supplementation can effectively blunt inflammation and related diseases in vivo. 34 -36 Therefore, we reasoned that dietary supplementation with fish oil-derived -3 PUFAs may prevent the SFA-driven TLR4 hypersensitivity and accelerated atherosclerosis seen with SCD1 inhibition. 21
Methods
Male low-density lipoprotein receptor-deficient (LDLr Ϫ/Ϫ ), apolipoprotein B 100 only (ApoB 100/100 ) mice were treated with antisense oligonucleotides (ASOs) to inhibit SCD1 while consuming diets containing 0.1% (w/w) cholesterol and 12% of energy as primarily either SFA-enriched fat (palm oil) or long chain -3 PUFA-enriched fat (fish oil) for 20 weeks as previously described. 21 Detailed descriptions of diets, materials, and experimental methods are available in the supplemental materials (available online at http://atvb.ahajournals.org).
Results

SCD1 ASO Treatment and Dietary Fish Oil Reduce SCD1 Expression in a Tissue-Specific Manner, Resulting in Protection Against
Diet-Induced Obesity and Insulin Resistance
There is a large body of evidence that either SCD1 inhibition or dietary fish oil alone can protect against diet induced obesity and insulin resistance in rodents. 4 -11,30 -36 However, the possibility that the combination of these 2 treatments can act synergistically to improve the metabolic syndrome has never been addressed. Interestingly, both SCD1 ASO treatment and dietary fish oil can diminish SCD1 expression in a tissue-specific manner (supplemental Figure 1 ), resulting in dramatic protection against diet-induced obesity and insulin resistance (supplemental Figure 2) . A detailed description of these anticipated metabolic improvements is provided in the supplemental materials.
Dietary Fish Oil Supplementation Prevents SCD1 ASO-Driven Atherosclerosis
We have previously shown that the SCD1 inhibition in hyperlipidemic mice fed either SFA-rich or monounsaturated fatty acid (MUFA)-rich diets results in more extensive atherosclerosis. 21 This unforeseen side effect of SCD1 inhibition was associated with SFA enrichment of plasma lipids and macrophage membranes, together with enhanced TLR4-driven proinflammatory signaling. Importantly, long chain -3 PUFAs have been shown to prevent SFA-induced TLR4 activation in cultured cells. 28, [31] [32] [33] [34] Therefore, we set out to test whether this relationship held up in vivo by examining atherosclerosis, a complex disease with an inflammatory component that is promoted by both SFA 37, 38 and TLR4 activation. 39, 40 As previously demonstrated, en face morphometric analysis showed that SCD1 ASO treatment in mice fed a SFA-rich diet resulted in a 2.7-fold increase in total aortic lesion area, compared to mice treated with a control ASO ( Figure 1A ). In parallel, SCD1 inhibition in mice fed a SFA-rich diet also resulted in increased concentrations of aortic cholesteryl ester ( Figure 1B ), aortic free cholesterol ( Figure 1C ), and abundant areas of necrosis with visible cholesterol crystals ( Figure 1D ), all indicating accelerated atherosclerosis. In contrast, in mice fed a fish oil diet, SCD1 ASO treatment had no significant effects on lesion area ( Figure 1A ), aortic cholesteryl ester ( Figure 1B) , and aortic free cholesterol ( Figure 1C ), or lesion complication ( Figure 1D and 1E), compared to control ASO treated mice. The chemical measurement may have been the most precise quantification of atherosclerosis, and mice fed a fish oil diet had significantly less aortic cholesteryl ester, compared to SFA-fed mice regardless of ASO treatment ( Figure 1B ). After 20 weeks of induction, the rank order of aortic cholesteryl ester for the groups was: SFA-fed/SCD1 ASO (118 g/mg protein)ϾSFA-fed/Control ASO (73 g/mg protein)ϾFish-oil fed/Control ASO (29 g/mg protein)ϾFish oil-fed/SCD1 ASO (5 g/mg protein).
Dietary Fish Oil Supplementation and SCD1 ASO Treatment Improve Atherogenic Hyperlipidemia in a Complimentary Fashion
In agreement with previous reports, 6,12-14 SCD1 inhibition alone and dietary fish oil alone prevented diet-induced hypertriglyceridemia, which was apparent after only 4 weeks of either treatment (Figure 2A ). After 8 weeks of treatment, the rank order of the groups for plasma TG was: SFA-fed/ Control ASO (201 mg/dL)ϾSFA-fed/SCD1 ASO (118 mg/ dL)ϾFish oil-fed/Control ASO (113 mg/dL)ϾFish oil-fed/ SCD1 ASO (76 mg/dL). In contrast to plasma TG, SCD1 ASO treatment only modestly reduced total plasma cholesterol (TPC) after 20 weeks in mice fed the SFA diet. TPC was not significantly altered after 4 or 8 weeks of this treatment ( Figure 2B ). Furthermore, in the fish oil-fed group, SCD1 ASO treatment did not produce a TPC lowering effect ( Figure  2B ). When lipoprotein cholesterol distribution was analyzed, we discovered that SCD1 inhibition alone and fish oil feeding alone decreased VLDL cholesterol compared to their respective controls ( Figure 2C ), but the 2 treatments together were not synergistic in lowering VLDLc. Interestingly, SCD1 ASO treatment had no effect on LDLc regardless of diet ( Figure  2D ). In contrast, dietary fish oil significantly reduced LDLc, compared to SFA-fed groups, regardless of ASO treatment ( Figure 2D ). Furthermore, both SCD1 ASO treatment and dietary fish oil caused significant reductions in plasma HDLc ( Figure 2E ). As previously described, 21 SCD1 ASO treatment caused marked enrichment of LDL cholesteryl esters (LDL-CE) with saturated FA in both diet groups ( Figure 2F ). Also, dietary fish oil supplementation resulted in the expected -3 PUFA-enrichment in LDL-CE ( Figure 2F ). Interestingly, ASO-mediated inhibition of SCD1 in fish oil-fed mice caused significantly more -3 PUFAs to be incorporated in LDL-CE, compared to control ASO treated mice. It seems the primary effects of SCD1 inhibition alone are: diminished plasma triglyceride, decreased VLDLc, and enrichment of plasma lipoproteins with SFA. In contrast, dietary fish oil effectively reduces both plasma TG and LDLc levels. Collectively, the effects of SCD1 ASO and dietary fish oil synergistically improve atherogenic hyperlipidemia, likely through independent mechanisms.
Dietary Fish Oil Supplementation Prevents SCD1 ASO-Driven TLR4 Hypersensitivity in Macrophages
SCD1 ASO treatment for 6 weeks reduced the palmitoleate (16:1) to palmitate (16:0) ratio in macrophage PL in both diet groups ( Figure 3A ). This was anticipated because we have previously demonstrated that SCD1 ASO treatment reduces macrophage SCD1 expression. 21 Dietary fish oil alone did not alter the 16:1 to 16:0 ratio in macrophage PL, compared to PL isolated from SFA-fed mice ( Figure 3A) , and did not alter macrophage SCD1 mRNA levels ( Figure  3C ). However, dietary fish oil supplementation resulted in expected -3 PUFA-enrichment in macrophage PL ( Figure  3A ). As seen in plasma ( Figure 2F ) and the liver (supplemental Figure 3D ), ASO-mediated inhibition of SCD1 in mice fed a fish oil diet caused a trend toward increased -3 PUFA incorporation into macrophage PL, compared to control ASO-treated mice. It has previously been demonstrated that macrophage SCD1 plays a role in cellular cholesterol efflux, 41 which could subsequently impact atherogenesis. However, we did not see any appreciable effects of diet or SCD1 ASO treatment on cellular cholesterol efflux to either lipid-free apoAI or HDL ( Figure 3B ). More importantly, when macrophages isolated from SCD1 ASO-treated mice fed a SFA-rich diet were challenged with a specific TLR4 agonist (10 ng/mL Kdo 2 -Lipid A), marked hypersensitivity was apparent, both at the mRNA level ( Figure 3C ) and the level of protein secretion ( Figure  3D ) as previously described. 21 In support of this, TLR4dependent upregulation of inflammatory gene expression . Dietary fish oil supplementation prevents SCD1 ASO-driven TLR4 hypersensitivity in macrophages. Starting at 6 weeks of age, male mice were fed diets containing 0.1% (w/w) cholesterol enriched in either saturated (Sat.) or long chain -3 fatty acids (Fish) for 6 weeks in conjunction with biweekly injections (25 mg/kg) of a nontargeting control ASO (Cont.) or SCD1 ASO (SCD1). After 6 weeks of diet and ASO treatment, freshly isolated thioglycollate-elicited macrophages were pooled (nϭ5 to 7 mice per pool) and cultured as described in materials and methods. A, Phospholipid fatty acid (PL-FA) composition (16:1 to 16:0 ratio and % of total FA as long chain -3 [eicosapentaenoic and docosahexaenoic] fatty acids) of freshly isolated (2-hour culture) macrophages. B, Macrophage cholesterol efflux to apoAI (10 g/mL) or high-density lipoprotein (HDL, 50 g/mL). C, TLR4-driven gene expression: Freshly isolated macrophages were treated with vehicle or 10 ng/mL Kdo 2 -Lipid A (TLR4 agonist) for 6 hours, and mRNA levels were measured for interleukins 1 beta (IL-1␤), 6 (IL-6), and 12p40 (IL-12p40), tumor necrosis factor ␣ (TNF␣), C-X-C motif ligand 10 (IP-10), and gluocorticoid attenuated response gene 16 (Garg-16), and normalized to GAPDH. Data shown in panel C are expressed as the mean relative mRNA expression, where all values were normalized to the levels in the Sat. -Control vehicle treated group, and the SEM was calculated from triplicate plates for each pool. D, TLR4-driven cytokine secretion: Freshly isolated macrophages were treated with vehicle or 10 ng/mL Kdo 2 -Lipid A (TLR4 agonist) for 6 hours, and cytokine levels (pg/mL) were measured for IL-1␤, IL-6, IL-12p40, TNF␣, Chemokine C-X-C motif ligand 1 (KC), Regulated on Activation Normal T-cell Expressed and Secreted (RANTES,) monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1 alpha (MIP-1␣) using conditioned media. Data shown in panel D the meanϮSEM from triplicate plates for each pool. N.D. indicates values not detectable.
was much more robust in macrophages isolated from SFA-rich diet-fed mice treated with SCD1 ASO, compared to macrophages isolated from their counterparts treated with control ASO ( Figure 3C ). Likewise, TLR4-dependent promotion of inflammatory cytokine secretion was much more robust in macrophages isolated from SFA-rich dietfed SCD1 ASO-treated mice, compared to macrophages isolated from their counterparts treated with control ASO (Figure 3D ). In contrast, in mice fed a -3 PUFA-rich diet, SCD1 ASO treatment did not result in TLR4 hypersensitivity ( Figure 3C and 3D) . Interestingly, plasma levels of inflammatory cytokines were relative low in all the experimental groups (supplemental Table II ) and were not significantly different with SCD1 ASO treatment. Collectively, these data suggest that SCD1 ASO-driven TLR4 hypersensitivity in macrophages can be prevented by dietary fish oil supplementation.
Combined Therapy of Dietary Fish Oil and SCD1 ASO Prevents Diet-Induced Hepatic Steatosis
Mice lacking SCD1 are protected against diet-and genetically-induced hepatic steatosis. 13, 14, 17, 20, 21 Likewise, dietary -3 PUFA supplementation protects against hepatic steatosis in a number of experimental models. 6, 22 Interestingly, the dual therapy of dietary fish oil and SCD1 ASO treatment resulted in near complete prevention of dietinduced hepatic steatosis (supplemental Figure 3) . A detailed description of these data are provided in the supplemental material.
Discussion
The search for metabolic syndrome targets has strongly supported SCD1 inhibitors as an attractive option for preventing obesity, insulin resistance, hypertriglyceridemia, and hepatic steatosis. 4 -16 Unfortunately, there are severe side effects associated with diminished SCD1 activity in mice, including skin pathology [17] [18] [19] [20] and accelerated atherosclerosis. 21, 22 These warning signs have unfortunately impeded many SCD1 inhibitor programs, 42 without complete understanding of the etiology of these complex side effects. It is logical to assume many of the side effects seen with SCD1 inhibition stem from the abnormal accumulation of SFAs in multiple tissues. Indeed, SFAs are potent proinflammatory molecules 24 -34 and have been linked to innate immunity. 24, 28, 29, [31] [32] [33] [34] Therefore, SCD1 may indirectly suppress inflammation by preventing SFA-induced activation of TLR4. The concept of fatty acids regulating inflammation is not unique to SFAs. In fact, long chain -3 PUFA from fish oil have been shown to inhibit inflammation, and more importantly, counteract SFA-induced TLR4 activation in cultured cells. 28,30 -33 This study provides new evidence that this reciprocal relationship between SFA and -3 PUFA in modulating inflammation also holds true in vivo, and can be exploited to protect against multiple metabolic diseases.
The question now becomes: how does the combination of SCD1 ASO treatment and dietary fish oil synergize to comprehensively prevent the development of obesity, insulin resistance, hyperlipidemia, hepatic steatosis, and atherosclerosis? There are likely both shared and independent mechanisms by which these treatments mediate their effects. When given as a monotherapy, SCD1 ASO treatment results in striking protection against diet-induced obesity, 7,21 insulin resistance, 7,10,21 hypertriglyceridemia, 7,21 and hepatic steatosis. 7, 21 Unfortunately, SCD1 ASO treatment promotes severe atherosclerosis in hyperlipidemic mice fed either a SFA-or MUFA-rich diet. 21 We believe that dietary fish oil supplementation is able to prevent SCD1 ASO-driven atherosclerosis through at least 3 independent mechanisms: (1) lowering LDLc, (2) enriching the remaining LDL-CE in atheroprotective -3 PUFAs, and (3) counteracting SFA-driven inflammation. In support of this, dietary fish oil lowered LDLc by 47% to 53%, compared to SFA-fed mice regardless of ASO treatment ( Figure 2D ). However, the LDL-CE remaining in fish oil fed mice treated with SCD1 ASO was highly enriched in -3 PUFAs, yet enriched in SFA to the same extent as SFA-fed SCD1 ASO-treated mice ( Figure 2F ). These results indicate that dietary fish oil does not diminish SCD1 ASO-mediated SFA enrichment of plasma lipids, but rather shifts the fatty acid composition to be more polyunsaturated, which has the potential to diminish the production of VLDLc 45 ( Figure 2C ). In this regard, it has been previously demonstrated that long chain fatty acids such as docosahexaenoic acid (DHA) can inhibit VLDL secretion by promoting post-ER presecretory proteolysis (PERPP)-mediated degradation of apolipoprotein B 46 or endoplasmic reticulum (ER) stress-related degradation of apoB. 47 Although we did not directly measure oxidant stress or PERPP, we saw no indication that either fish oil or SCD1 ASO promoted hepatic ER stress (supplemental Figure 4 ).
It is important to note that SCD1 ASO treatment unexpectedly results in a dramatic HDLc reduction in hyperlipidemic mice fed a SFA-rich diet. 21 Based on this, it has recently been speculated that SCD1 ASO-driven HDLc lowering may be the cause of accelerated atherosclerosis seen under these conditions. 22 However, our data suggest that HDLc lowering plays little, if any, role in SCD1 ASO-driven accelerated atherosclerosis. In support of this, dietary fish oil alone actually decreased HDLc, compared to SFA-fed mice ( Figure  2E ), yet atherosclerosis was also decreased in fish oil-fed mice. Most importantly, fish oil supplementation did not prevent SCD1 ASO-mediated reductions in HDLc seen in SFA-fed mice (Figure 2E ). In fact, the mice treated with SCD1 ASO and fed dietary fish oil had the lowest HDLc of any group with the rank order of the 4 groups being: SFA-fed/Control ASO (79 mg/dL)ϾFish oil-fed/Control ASO (49 mg/dL)ϾSFA-fed/SCD1 ASO (35 mg/dL)ϾFish oil-fed/SCD1 ASO (30 mg/dL). Collectively, these data suggest that HDLc modulation is not the primary mechanism by which dietary fish oil protects against SCD1 ASO-driven atherosclerosis.
In addition to reducing plasma lipoprotein levels, dietary fish oil prevents SCD1 ASO-driven TLR4 hypersensitivity ( Figure 3C ). This may be attributable, in part, to the enrichment of macrophage membranes with long chain -3 PUFAs ( Figure 3A) , which are known to prevent SFAdriven TLR4 activation. 28,30 -33 Importantly, SCD1 ASO treatment results in marked accumulation of SFA in plasma, multiple tissues, and isolated macrophages ( Figure  2F Figure 3A ). Hence, even in the face of massive SCD1 ASO-driven SFA accumulation, moderate dietary -3 PUFA supplementation can prevent SFA-driven inflammation ( Figure 3C ) and atherosclerosis (Figure 1 ). This makes it tempting to speculate that the other diverse pathologies associated with genetic deletion of SCD1, 11, [17] [18] [19] [20] 23 including alopecia, might likewise be ameliorated by the antiinflammatory effects of dietary fish oil. Interestingly, during the preparation of this manuscript, a recent study warned that previous work 29 -33 describing SFA-mediated activation of TLR4 or TLR2 may have been confounded by contamination of the fatty acid vehicle (BSA) with LPS or bacterial lipoproteins. 48 Importantly, because in vivo dietary feeding of long-chain fatty acids does not require a BSA vehicle, this is likely not the only explanation for SFA-induced TLR4 activation. Rather, our results provide in vivo evidence that saturated fatty acids do indeed promote TLR4-dependent signaling and that n-3 PUFAs can antagonize SFA-driven TLR4 hypersensitivity ( Figure  3 ). However, whether fatty acids exert their effects through direct TLR4 agonism or by modulating membrane organization is still a matter of debate and requires further work.
It is important to point out that ASO-mediated inhibition of SCD1 does not alter SCD1 protein expression in the skin or result in alopecia. 21 This tissue-specific pattern of inhibition seen with in vivo ASO administration has been documented previously 43, 44 and is ideal for SCD1 inhibition where tissue specificity is required to avoid unwanted side effects. In a recent study by MacDonald and colleagues, 22 it was speculated that the accelerated atherosclerosis seen with genetic SCD1 deficiency was in part attributable to dermal inflammation. 22 This is unlikely to be the primary mechanism for the accelerated atherosclerosis, because SCD1 ASO treatment also results in severe atherosclerosis, without affecting skin SCD1 expression or alopecia. 21 Therefore, ASO-mediated inhibition may provide a unique tissue-specific therapeutic strategy to avoid the skin pathology 17-20 that would likely accompany small molecule SCD1 inhibitors without tissue specificity.
In summary, we have demonstrated that SCD1 ASO treatment protects against development of the metabolic syndrome but unfortunately promotes atherosclerosis in mice fed diets enriched in either SFA or MUFA. 6 However, SCD1 ASO-driven atherosclerosis can be completely prevented by dietary fish oil (Figure 1) . Importantly, the proinflammatory effects of SCD1 ASO treatment can be overcome by dietary -3 PUFA supplementation, and the dual therapy provides dramatic protection against atherogenic hyperlipidemia. Therefore, this synergistic dual therapy may provide a novel therapeutic approach for the metabolic syndrome and atherosclerosis.
